Market›Health Care›Biotechnology›Biotechnology
SERNOVA BIOTHERAPEUT

SEOVF

$0.13Apr 26, 2021 – Apr 24, 2026
Health CareBiotechnology$42M
MVM
+$0.0M

Every news event mapped to its market reaction — 26 events, 61 months of data. No predictions, just what happened.

PositiveNegativeNo data· Dot size = magnitude · Scroll to zoom · Drag to pan
Hover to inspect

Want the full written briefing?

The chart shows what moved — the briefing shows why. Sourced, dated, no hot takes.

Subscribe on Substack →

News Events

DateReturnCategorySourceHeadline
2026-03-04+19.9%executiveTMX NewsfileSernova Biotherapeutics Strengthens Balance Sheet with $7.1 Million in Financings Plus Net Retirement of a Cumulative $17 Million of Debt Subject to Shareholder Approval
2026-04-09+16.2%newsTMX NewsfileSernova Biotherapeutics Announces Affirmative Voting Results from 2026 Annual General Meeting of Shareholders
2026-04-09+16.2%newsStock TitanSernova wins shareholder approval for $12.5M debt swap - Stock Titan
2025-05-26-9.2%executiveSeeking AlphaSernova Biotherapeutics says chair Ross Haghighat resigns
2023-05-03+9.0%newsSeeking AlphaSernova joins hands with AstraZeneca for potential therapeutic cell applications
2026-03-24-7.9%newsTMX NewsfileSernova Biotherapeutics Announces Close of Non-Brokered Private Placement Financing
2026-03-24-7.9%newsTMX NewsfileSernova Biotherapeutics Announces Close of Non-Brokered Private Placement Financing - TMX Newsfile
2024-08-12-7.0%executiveSeeking AlphaSernova names Rigby as new CEO
2025-03-03-4.2%legalStock TitanCould This FDA-Cleared Thyroid Therapy End Lifetime Medication Dependence? - Stock Titan
2025-03-10-3.7%executiveStock TitanSernova Strengthens Diabetes Treatment Program With New R&D Chief - Stock Titan
2024-01-29-2.8%newsSeeking AlphaSernova reports anticipated 2024 milestones
2023-09-05+2.7%executiveSeeking AlphaSernova appoints CEO
2023-11-27+1.9%legalSeeking AlphaSernova gets FDA orphan drug, rare pediatric designations for hemophilia A
2026-03-05+1.9%legalStreetwise ReportsBiotech With Groundbreaking Diabetes Treatment Secures CA$7.1M Breakthrough Financing - Streetwise Reports
2024-10-11-1.4%executiveSeeking AlphaSernova names James Parsons as CFO
2022-12-06-1.4%executiveSeeking AlphaSernova appoints Philip Toleikis as CTO; to look for new CEO
2025-07-09-0.9%newsStock TitanBreakthrough: New Drug Collaboration Shows 5X Better Results in Type 1 Diabetes Cure Trial - Stock Titan
2025-03-05+0.7%legalSeeking AlphaSernova Biotherapeutics secures CAD$1M convertible debt financing
2025-10-01-0.5%newsSeeking AlphaSernova converts $13.3M debt to equity ahead of clinical milestone
2025-10-01-0.5%newsTMX NewsfileSernova Biotherapeutics Announces $13 Million Debt-to-Equity Conversion Eliminating Significant Financing Overhang - TMX Newsfile
2026-04-23-0.4%newsTMX NewsfileSernova Biotherapeutics Announces Closing of Recently Approved Financings
2026-04-23-0.4%newsStock TitanSernova converts $12.5M in vendor debt into equity - Stock Titan
2026-02-20+0.3%newsTMX NewsfileSernova Biotherapeutics Announces Warrant Amendments
2026-02-20+0.3%newsSeeking AlphaSernova to amend warrants, extend expiry, and cut exercise price
2026-02-20+0.3%newsStock TitanSernova gives warrant holders more time and lower exercise prices - Stock Titan
2025-07-15+0.1%expansionStreetwise ReportsBiotech Partnership to Revolutionize Diabetes Treatment - Streetwise Reports
tickerdossier.comtickerdossier.substack.com